Daewoong Pharmaceutical Collaborate with IPB to Enhance Preclinical Drug Research in Indonesia
Daewoong Pharmaceutical announced on June 28 that it will embark on primate research in collaboration with Bogor Agricultural University (IPB), which boasts Indonesia's top veterinary research capabilities. This partnership aims to enhance preclinical competitiveness and foster new drug development, marking a pivotal step in the pharmaceutical and biotechnological landscape of Indonesia.
Daewoong Pharmaceutical and IPB have signed a Memorandum of Understanding (MOU) to establish a specialized primate research institute at IPB. This agreement encompasses the commercialization of pharmaceuticals and medical devices through primate research and supports the growth of talented veterinarians. The collaboration will be carried out with PSSP, an IPB-affiliated institution with over 30 years of experience in primate research, which obtained full AAALAC accreditation in 2006.
The specialized primate research institute aims to enhance the reliability of preclinical results by studying primates with naturally occurring diseases similar to those in humans. This initiative is crucial for securing competitiveness in the preclinical stage, where the toxicity and efficacy of new drug candidates are evaluated before human trials.
Daewoong Pharmaceutical entered the Indonesian market by establishing its Jakarta branch in 2005. Since then, the company has been actively pursuing new businesses and research in Indonesia across the healthcare and beauty sectors, including pharmaceutical manufacturing facilities, stem cell research, and aesthetic clinics.
PSSP, the Primate Research Center affiliated with IPB, has been a cornerstone of primate research in Indonesia. With its full AAALAC accreditation, PSSP has conducted joint research with overseas researchers from the United States, Denmark, and other countries, accumulating diverse experiences in primate research with major international institutions. AAALAC, the Association for Assessment and Accreditation of Laboratory Animal Care International, is an international non-profit organization that sets and evaluates standards for animal experimentation ethics and welfare.
The collaboration between Daewoong Pharmaceutical and IPB is expected to drive significant advancements in preclinical studies, which are essential for evaluating the safety and efficacy of new drug candidates before human trials. By leveraging IPB's top-tier veterinary research capabilities and Daewoong's pharmaceutical expertise, the partnership aims to create a robust platform for innovative drug development.
In addition to the research collaboration with IPB, Daewoong Pharmaceutical is also exploring new opportunities in Indonesia's healthcare and beauty sectors. The company's commitment to expanding its presence in Indonesia underscores the potential for growth and innovation in the region's pharmaceutical and biotechnology industries.
As the collaboration progresses, both Daewoong Pharmaceutical and IPB anticipate that the establishment of the specialized primate research institute will not only enhance preclinical research but also contribute to the development of Indonesia's pharmaceutical and bio industries. The partnership is poised to create new opportunities for scientific advancement, economic economic growth, and the cultivation of skilled professionals in the field of veterinary and pharmaceutical research.
July 1, 2024
